Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives 'Buy' Rating and $14.00 Price Target from CB Capital Partners
Emeryville, California – Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”) is a clinical-stage biopharmaceutical company dedicated to developing ARTEMIS targeting CD19 and CD22®T-cell therapy for the treatment of cancer and autoimmune diseases. The company announced today that CB Capital Partners has initiated analyst coverage with a “Buy” rating and set a target price of $14.00.
“We thank CB Capital for the company’s proprietary ARTEMIS®“...a detailed evaluation of the T-cell platform and recognition of the progress made in the EB103 program,” said Dr. Liu Cheng, President and CEO of Estrella. “The report highlights the unique advantages of our T-cell therapies and underscores the potential of our pipeline to deliver transformative treatments for cancer patients.”
The core viewpoints of the CB Capital report include:
■ Superior Safety and Efficacy:
Estrella's ARTEMIS®By enhancing T-cell persistence, tumor specificity, and overall safety, the platform aims to overcome the limitations of conventional CAR-T therapies. Clinical data for EB103 demonstrate high response rates, with no occurrences of severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), positioning it as a potential “best-in-class” therapy for hematologic malignancies.
■ Expanding Patient Accessibility:
EB103 addresses unmet clinical needs by targeting high-risk non-Hodgkin lymphoma (NHL) patients, including those with HIV-associated lymphoma and central nervous system lymphoma. Its favorable safety profile and low toxicity enable broader adoption in non-specialized medical centers, thereby benefiting more underserved cancer patients.
■ Strong Strategic Appeal:
ARTEMIS®The platform’s innovative design and clinical potential make Estrella a prime candidate for strategic investment, technology licensing, or mergers and acquisitions. Eligibility for expedited regulatory review pathways and the potential for orphan drug designation further enhance the company’s long-term investment value.
CB Capital Partners, established in 2001, specializes in providing investment banking services to enterprises, helping them seize opportunities amidst shifts in the business cycle. Leveraging decades of transaction experience and deep insights into market dynamics, its founding team—including former Goldman Sachs and CBRE member Chris Baclawski—assists clients in achieving their strategic and financial objectives. By analyzing financing options, connecting clients with strategic capital, and facilitating structured negotiations, the firm helps clients maximize value in mergers and acquisitions and financing activities.
EB103 is a T-cell therapy, also known as Estrella’s “CD19-redirected ARTEMIS”®“T-cell therapy” adopts ARTEMIS, licensed from its parent company Eureka Therapeutics, Inc. (“Eureka”)®Technology. Unlike traditional CAR-T cells, ARTEMIS®The unique design of T cells (such as EB103 T cells) enables their activation and regulation upon binding to cancer targets, utilizing cellular mechanisms that more closely resemble those triggered by endogenous T cell receptors. Once infused, EB103 T cells can recognize and target CD19-positive cancer cells, thereby eliminating them.
Estrella is a clinical-stage biopharmaceutical company dedicated to developing ARTEMIS targeting CD19 and CD22.®T-cell therapies for the treatment of cancer and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to improve the quality of life for patients with cancer and other diseases. To fulfill this mission, Estrella’s lead candidate product, EB103, leverages Eureka’s ARTEMIS®The technology targets CD19, a protein expressed on the surface of nearly all B-cell leukemias and lymphomas. Estrella is also developing EB104, which similarly leverages Eureka’s ARTEMIS®Technology capable of simultaneously targeting CD19 and CD22, two proteins expressed on the surface of most B-cell malignancies.
For more information about Estrella, please visitwww.estrellabio.com。
Forward-Looking Statements
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, those regarding EB103 and ARTEMIS®The potential benefits and therapeutic advantages of T-cell therapy, the anticipated progress and milestones of the STARLIGHT-1 Phase I/II clinical trial, the potential of EB103 to address the limitations of currently marketed CAR-T therapies, and statements regarding the future development plans for EB103 are all based on management’s current expectations, estimates, forecasts, and projections concerning the industry and market, as well as management’s current beliefs and assumptions. These statements can be identified by the use of forward-looking terminology, including but not limited to “anticipate,” “expect,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “will,” and similar expressions and the negative forms of these terms. These statements involve future events or our financial performance and contain known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause actual results to differ materially from current expectations include, but are not limited to, those listed under “Risk Factors” in our filings with the U.S. Securities and Exchange Commission and elsewhere. The forward-looking statements in this press release reflect our views only as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may update these forward-looking statements at some point in the future, we have no current intention of doing so except as required by law. Therefore, you should not rely on these forward-looking statements as representing our views as of any date after the date of this press release.
The Company previously entered into a cooperation agreement with CB Capital Partners, under which CB Capital will serve as the financial advisor to assist in preparing the initial coverage research report (the “Report”) and independently analyze Estrella’s business model, financial prospects, and market positioning. The Report covers a comprehensive assessment of the Company’s development history, strategic objectives, financial forecasts, and industry peer benchmarks.
Investors can access the full report through CB Capital Partners or its affiliated research platform.
The target price and rating set by CB Capital Partners represent only its independent view on the company’s securities. Estrella does not endorse or confirm the accuracy or conclusions of this report. The rating does not constitute a recommendation to buy, sell, or hold securities; investors should conduct a comprehensive assessment in conjunction with other market information. The target price may be subject to deviations due to market risks, macroeconomic conditions, and future events; investors should exercise caution when referring to it.
Contact Information
Investor Relations
Estrella Immunopharma, Inc.
IR@estrellabio.com